PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24069041-6 2013 Despite the lack of a granule localized storage pool of receptors, the PAF-induced superoxide production could be primed; receptor mobilization was, thus, not required for priming of the PAF response. Superoxides 83-93 PCNA clamp associated factor Homo sapiens 71-74 12771544-8 2003 In contrast, PAF-induced superoxide generation was inhibited by treatment with BisI, myr-psiPKC and rottlerin. Superoxides 25-35 PCNA clamp associated factor Homo sapiens 13-16 17135294-9 2007 pGSN also markedly inhibited PAF-induced superoxide anion (O(2)(-)) production of human peripheral neutrophils (PMN) in a concentration-dependent manner (P < 0.0001). Superoxides 41-57 PCNA clamp associated factor Homo sapiens 29-32 17135294-9 2007 pGSN also markedly inhibited PAF-induced superoxide anion (O(2)(-)) production of human peripheral neutrophils (PMN) in a concentration-dependent manner (P < 0.0001). Superoxides 59-64 PCNA clamp associated factor Homo sapiens 29-32 17135294-10 2007 A phospholipid-binding peptide derived from pGSN (QRLFQVKGRR) also inhibited PAF-mediated O(2)(-) generation (P = 0.024). Superoxides 90-94 PCNA clamp associated factor Homo sapiens 77-80 15264222-5 2004 A nonneurotoxic PAF concentration (500 nM) potentiated neuronal death caused by hydrogen peroxide as determined by lactate dehydrogenase (LDH) assay, Hoechst staining, and TUNEL analysis, but it did not potentiate neuronal death caused by menadione, a superoxide donor, or by the nitric oxide donors 3-morpholino-sydnonimine (SIN-1) and sodium nitroprusside (SNP). Superoxides 252-262 PCNA clamp associated factor Homo sapiens 16-19 15166482-1 2004 Platelet-activating factor (PAF) induces various cellular functions in eosinophils including chemotaxis, adhesion, superoxide anion (O2-) production, and degranulation. Superoxides 115-131 PCNA clamp associated factor Homo sapiens 0-26 15166482-1 2004 Platelet-activating factor (PAF) induces various cellular functions in eosinophils including chemotaxis, adhesion, superoxide anion (O2-) production, and degranulation. Superoxides 115-131 PCNA clamp associated factor Homo sapiens 28-31 15166482-1 2004 Platelet-activating factor (PAF) induces various cellular functions in eosinophils including chemotaxis, adhesion, superoxide anion (O2-) production, and degranulation. Superoxides 133-136 PCNA clamp associated factor Homo sapiens 0-26 15166482-1 2004 Platelet-activating factor (PAF) induces various cellular functions in eosinophils including chemotaxis, adhesion, superoxide anion (O2-) production, and degranulation. Superoxides 133-136 PCNA clamp associated factor Homo sapiens 28-31 12771544-9 2003 CONCLUSIONS: PKCalpha, beta and delta are not involved in PAF-induced CD11b expression, but PKCdelta is involved in the PAF-induced activation of superoxide anion generation. Superoxides 146-162 PCNA clamp associated factor Homo sapiens 120-123 12391244-3 2002 To investigate the molecular mechanisms of the responses of eosinophils to PAF, we analyzed superoxide anion production by a chemiluminescence method that provides real-time kinetic data for the cellular responses. Superoxides 92-108 PCNA clamp associated factor Homo sapiens 75-78 12391244-4 2002 We found that PAF induced bimodal superoxide anion production in human eosinophils, consisting of an intense, but transient, first phase and a larger and sustained second phase. Superoxides 34-50 PCNA clamp associated factor Homo sapiens 14-17 12126473-7 2002 It is concluded that superoxide production by leukocytes of healthy individuals and especially by leukocytes of hypercholesterolemic individuals is process that depends on PAF or PAF-like lipids. Superoxides 21-31 PCNA clamp associated factor Homo sapiens 172-175 12126473-0 2002 Influence of platelet-activating factor, its cell analogs, and antagonist on the production of superoxide radicals by blood leukocytes of healthy and hypercholesterolemic individuals. Superoxides 95-105 PCNA clamp associated factor Homo sapiens 13-39 12126473-7 2002 It is concluded that superoxide production by leukocytes of healthy individuals and especially by leukocytes of hypercholesterolemic individuals is process that depends on PAF or PAF-like lipids. Superoxides 21-31 PCNA clamp associated factor Homo sapiens 179-182 12126473-1 2002 The influence of the phospholipid platelet-activating factor (PAF), its cell analogs, and lipid PAF antagonist on the production of superoxide radicals by leukocytes isolated from the blood of healthy and hypercholesterolemia IIA individuals was studied. Superoxides 132-142 PCNA clamp associated factor Homo sapiens 62-65 11303730-11 2001 However, both combinations of PAF/lyso-PCs and lyso-PCs/PAF significantly augmented O2- production and PMN adherence. Superoxides 84-86 PCNA clamp associated factor Homo sapiens 30-33 12126473-1 2002 The influence of the phospholipid platelet-activating factor (PAF), its cell analogs, and lipid PAF antagonist on the production of superoxide radicals by leukocytes isolated from the blood of healthy and hypercholesterolemia IIA individuals was studied. Superoxides 132-142 PCNA clamp associated factor Homo sapiens 96-99 12126473-3 2002 Exogenous PAF stimulates the superoxide production in the leukocytes of healthy individuals but significantly inhibits the superoxide production in the leukocytes of hypercholesterolemic individuals. Superoxides 29-39 PCNA clamp associated factor Homo sapiens 10-13 12126473-3 2002 Exogenous PAF stimulates the superoxide production in the leukocytes of healthy individuals but significantly inhibits the superoxide production in the leukocytes of hypercholesterolemic individuals. Superoxides 123-133 PCNA clamp associated factor Homo sapiens 10-13 12126473-5 2002 However, pretreatment of leukocytes by 1-alkenyl-PAF or PAF-antagonist (1-O-alk-1;-enyl-2-(2;-acetoxybenzoyl)-sn-glycero-3-phosphocholine) results in a 50% inhibition of the PAF-induced superoxide production by leukocytes of healthy individuals. Superoxides 186-196 PCNA clamp associated factor Homo sapiens 56-59 12126473-5 2002 However, pretreatment of leukocytes by 1-alkenyl-PAF or PAF-antagonist (1-O-alk-1;-enyl-2-(2;-acetoxybenzoyl)-sn-glycero-3-phosphocholine) results in a 50% inhibition of the PAF-induced superoxide production by leukocytes of healthy individuals. Superoxides 186-196 PCNA clamp associated factor Homo sapiens 56-59 12126473-6 2002 This PAF-antagonist alone or in combination with PAF induces a substantial (65-70%) inhibition of superoxide production in the leukocytes of hypercholesterolemic individuals. Superoxides 98-108 PCNA clamp associated factor Homo sapiens 5-8 12126473-6 2002 This PAF-antagonist alone or in combination with PAF induces a substantial (65-70%) inhibition of superoxide production in the leukocytes of hypercholesterolemic individuals. Superoxides 98-108 PCNA clamp associated factor Homo sapiens 49-52 11303730-11 2001 However, both combinations of PAF/lyso-PCs and lyso-PCs/PAF significantly augmented O2- production and PMN adherence. Superoxides 84-86 PCNA clamp associated factor Homo sapiens 56-59 11034409-0 2000 Capsaicin inhibits platelet-activating factor-induced cytosolic Ca2+ rise and superoxide production. Superoxides 78-88 PCNA clamp associated factor Homo sapiens 19-45 11034409-3 2000 Capsaicin inhibited PAF-induced superoxide production in a concentration-dependent manner. Superoxides 32-42 PCNA clamp associated factor Homo sapiens 20-23 11034409-11 2000 Both capsaicin and SK&F96365 also inhibited PAF-induced cytosolic superoxide generation in HL-60 cells differentiated by all-trans-retinoic acid. Superoxides 70-80 PCNA clamp associated factor Homo sapiens 48-51 9269528-3 1997 However, by day 2 of culture, PAF induced an increase in O2- generation that was inhibited by pretreatment with the PAF receptor antagonist WEB 2086. Superoxides 57-59 PCNA clamp associated factor Homo sapiens 30-33 10072549-5 1999 Human eosinophils produced superoxide when stimulated with immobilized IgG, soluble IL-5, or PAF. Superoxides 27-37 PCNA clamp associated factor Homo sapiens 93-96 10072549-8 1999 Furthermore, structurally distinct PAF antagonists, including CV6209, hexanolamine PAF, and Y-24180 (israpafant), inhibited IgG- or IL-5-induced superoxide production and degranulation. Superoxides 145-155 PCNA clamp associated factor Homo sapiens 35-38 10072549-8 1999 Furthermore, structurally distinct PAF antagonists, including CV6209, hexanolamine PAF, and Y-24180 (israpafant), inhibited IgG- or IL-5-induced superoxide production and degranulation. Superoxides 145-155 PCNA clamp associated factor Homo sapiens 83-86 10216433-3 1999 These cells responded to fMLP or PAF with an increase in [Ca2+]i, associated with O2 production. Superoxides 82-84 PCNA clamp associated factor Homo sapiens 33-36 10216433-4 1999 Deprivation or chelation of extracellular calcium induced a reduction of fMLP or PAF-induced [Ca2+]i rise and O2- production. Superoxides 110-112 PCNA clamp associated factor Homo sapiens 81-84 10886400-5 2000 PAF induced superoxide anion (O2-*) generation, leukotriene C4 (LTC4) release, intracellular calcium ion mobilization and tyrosine phosphorylation of multiple eosinophil proteins in a concentration-dependent manner. Superoxides 12-28 PCNA clamp associated factor Homo sapiens 0-3 10886400-5 2000 PAF induced superoxide anion (O2-*) generation, leukotriene C4 (LTC4) release, intracellular calcium ion mobilization and tyrosine phosphorylation of multiple eosinophil proteins in a concentration-dependent manner. Superoxides 30-32 PCNA clamp associated factor Homo sapiens 0-3 10202371-8 1999 Furthermore, enhanced O2- generation, but not adhesion, associated with IL-4 + TNFalpha-treatment of HUVEC was inhibited when EOS were treated with the platelet activating factor (PAF)-antagonist WEB 2086 (20 microM), thus suggesting an involvement of PAF in priming EOS. Superoxides 22-24 PCNA clamp associated factor Homo sapiens 180-183 10202371-8 1999 Furthermore, enhanced O2- generation, but not adhesion, associated with IL-4 + TNFalpha-treatment of HUVEC was inhibited when EOS were treated with the platelet activating factor (PAF)-antagonist WEB 2086 (20 microM), thus suggesting an involvement of PAF in priming EOS. Superoxides 22-24 PCNA clamp associated factor Homo sapiens 252-255 10216433-6 1999 Chelation of intracellular calcium induced an inhibition of fMLP- or PAF-induced [Ca2+]i rise and a decrease in O2- production. Superoxides 112-114 PCNA clamp associated factor Homo sapiens 69-72 9269528-3 1997 However, by day 2 of culture, PAF induced an increase in O2- generation that was inhibited by pretreatment with the PAF receptor antagonist WEB 2086. Superoxides 57-59 PCNA clamp associated factor Homo sapiens 116-119 9269528-8 1997 In contrast, pretreatment with the protein kinase C inhibitor staurosporine had no effect on PAF-induced tyrosine phosphorylation, but did inhibit PAF-induced O2- generation. Superoxides 159-161 PCNA clamp associated factor Homo sapiens 147-150 9291376-5 1997 Our hypothesis is that the well-recognized postinjury mediators platelet-activating factor (PAF) and leukotriene B4 (LTB4) prime PMNs for the concordant release of elastase and superoxide (O2-) as well as for CD11b up-regulation. Superoxides 177-187 PCNA clamp associated factor Homo sapiens 64-90 9291376-5 1997 Our hypothesis is that the well-recognized postinjury mediators platelet-activating factor (PAF) and leukotriene B4 (LTB4) prime PMNs for the concordant release of elastase and superoxide (O2-) as well as for CD11b up-regulation. Superoxides 177-187 PCNA clamp associated factor Homo sapiens 92-95 9291376-5 1997 Our hypothesis is that the well-recognized postinjury mediators platelet-activating factor (PAF) and leukotriene B4 (LTB4) prime PMNs for the concordant release of elastase and superoxide (O2-) as well as for CD11b up-regulation. Superoxides 189-191 PCNA clamp associated factor Homo sapiens 64-90 9291376-5 1997 Our hypothesis is that the well-recognized postinjury mediators platelet-activating factor (PAF) and leukotriene B4 (LTB4) prime PMNs for the concordant release of elastase and superoxide (O2-) as well as for CD11b up-regulation. Superoxides 189-191 PCNA clamp associated factor Homo sapiens 92-95 9224389-11 1997 Lexipafant attenuated the PAF-mediated upregulation of PMN .O2- production, CD11b expression, and elastase release in a dose dependent fashion. Superoxides 60-62 PCNA clamp associated factor Homo sapiens 26-29 9245567-1 1997 Platelet-activating factor (PAF) concordantly primes neutrophils (PMNs) for superoxide generation and elastase release. Superoxides 76-86 PCNA clamp associated factor Homo sapiens 0-26 9245567-1 1997 Platelet-activating factor (PAF) concordantly primes neutrophils (PMNs) for superoxide generation and elastase release. Superoxides 76-86 PCNA clamp associated factor Homo sapiens 28-31 9245567-4 1997 We hypothesized that beta-adrenergic neutrophil stimulation has disparate effects on PAF-mediated PMN superoxide generation versus elastase release. Superoxides 102-112 PCNA clamp associated factor Homo sapiens 85-88 8943870-4 1996 PAF did not stimulate respiratory burst activity directly, but caused a rapid (maximal at 10 minutes) and concentration-dependent (EC50 50.2 nmol/L) increase in N-formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated superoxide anion release. Superoxides 219-235 PCNA clamp associated factor Homo sapiens 0-3 9224389-1 1997 Platelet activating factor (PAF) enhances polymorphonuclear leukocyte (PMN) superoxide (.O2-) production, CD11b expression, and elastase release, all essential components in the pathophysiology of multiple-organ failure. Superoxides 76-86 PCNA clamp associated factor Homo sapiens 28-31 9224389-1 1997 Platelet activating factor (PAF) enhances polymorphonuclear leukocyte (PMN) superoxide (.O2-) production, CD11b expression, and elastase release, all essential components in the pathophysiology of multiple-organ failure. Superoxides 89-91 PCNA clamp associated factor Homo sapiens 28-31 8694859-3 1996 However, inhibition of superoxide generation by neutrophils activated with phorbol myristate acetate (PMA), opsonized zymosan (OZ), and arachidonate (AA) only occurred with higher concentrations of propranolol, and coincided with decreased intracellular calcium fluxes, phospholipase A2 (PLA2) activity and synthesis of platelet-activating factor (PAF). Superoxides 23-33 PCNA clamp associated factor Homo sapiens 320-346 8694859-5 1996 A mechanistic relationship between the anti-oxidative and membrane-stabilizing properties of propranolol was suggested by the observation that pretreatment of neutrophils with LPC or PAF eliminated the inhibitory effects of the drug on superoxide generation by PMA-activated neutrophils. Superoxides 236-246 PCNA clamp associated factor Homo sapiens 183-186 8694859-3 1996 However, inhibition of superoxide generation by neutrophils activated with phorbol myristate acetate (PMA), opsonized zymosan (OZ), and arachidonate (AA) only occurred with higher concentrations of propranolol, and coincided with decreased intracellular calcium fluxes, phospholipase A2 (PLA2) activity and synthesis of platelet-activating factor (PAF). Superoxides 23-33 PCNA clamp associated factor Homo sapiens 348-351 8567031-5 1995 The ability of LPS, IFN-gamma, TNF-alpha or PAF to maintain the high superoxide response was blocked by addition of inhibitors of serine proteases, either 4-(2-aminoethyl)-benzenesulphonyl fluoride (AEBSF) or 3,4-dichloroisocoumarin. Superoxides 69-79 PCNA clamp associated factor Homo sapiens 44-47 8567031-11 1995 We conclude that activity of a monocyte serine protease is required to maintain the high superoxide response in monocytes primed with LPS, IFN-gamma, TNF-alpha, or PAF. Superoxides 89-99 PCNA clamp associated factor Homo sapiens 164-167 7979944-9 1994 Interleukin 6 (10 ng/mL) combined with a nonpriming concentration of PAF (0.1 ng/mL) primed PMNs for superoxide production over a range of incubation times. Superoxides 101-111 PCNA clamp associated factor Homo sapiens 69-72 7791340-3 1995 Therefore, we hypothesized that reperfused gut secretes platelet activating factor (PAF) via PLA2 activation that is responsible for increased PMN chemotaxis and priming for superoxide (O2-) generation. Superoxides 174-184 PCNA clamp associated factor Homo sapiens 84-87 7791340-3 1995 Therefore, we hypothesized that reperfused gut secretes platelet activating factor (PAF) via PLA2 activation that is responsible for increased PMN chemotaxis and priming for superoxide (O2-) generation. Superoxides 186-188 PCNA clamp associated factor Homo sapiens 84-87 7791340-10 1995 Similarly, gut I/R supernatant primed PMNs for O2- (P < 0.05) compared to laparotomy, and this effect was abrogated by a PAF antagonist. Superoxides 47-49 PCNA clamp associated factor Homo sapiens 124-127 8571587-1 1995 A platelet-activating factor (PAF) antagonist was found to inhibit superoxide production in the leukocytes of patients with type IIA hypercholesterolemia. Superoxides 67-77 PCNA clamp associated factor Homo sapiens 2-28 8571587-1 1995 A platelet-activating factor (PAF) antagonist was found to inhibit superoxide production in the leukocytes of patients with type IIA hypercholesterolemia. Superoxides 67-77 PCNA clamp associated factor Homo sapiens 30-33 8571587-3 1995 The PAF-antagonist-induced inhibition of superoxide production was observed in the leukocytes from hypercholesterolemic patients whose plasma cholesterol levels varied from 8.3 to 14.0 mmole/l. Superoxides 41-51 PCNA clamp associated factor Homo sapiens 4-7 7712674-5 1995 RESULTS: Superoxide generation induced by the stimulating agents increased significantly, reaching a peak after 12 hours (+116% [p < 0.001] for fMLP and +66% [p < 0.05] for PAF). Superoxides 9-19 PCNA clamp associated factor Homo sapiens 179-182 7852836-6 1995 LTB4- and PAF-induced superoxide anion generation is enhanced by the diacyglycerol kinase inhibitor R59022, whereas aggregation induced by LTB4, but not PAF, is augmented. Superoxides 22-38 PCNA clamp associated factor Homo sapiens 10-13 7930587-0 1994 Endothelial cell-associated platelet-activating factor primes neutrophils for enhanced superoxide production and arachidonic acid release during adhesion to but not transmigration across IL-1 beta-treated endothelial monolayers. Superoxides 87-97 PCNA clamp associated factor Homo sapiens 28-54 7981927-2 1994 It is known that in human polymorphonuclear leukocytes (PMNs), the phorbol ester-induced generation of superoxide anion (respiratory burst) is effectively inhibited by STAR in a dose-dependent manner, whereas superoxide generation induced by chemoattractants, e.g. n-formyl-methionyl-leucyl-phenylalanine (FMLP) or PAF, is regulated biphasically by STAR. Superoxides 103-119 PCNA clamp associated factor Homo sapiens 315-318 7943259-3 1994 Eosinophils were isolated by negative immunoselection, and activation with 10(-7) M platelet-activating factor (PAF) was confirmed by measurements of eosinophil peroxidase (EPO) secretion and superoxide (O2-.) Superoxides 192-202 PCNA clamp associated factor Homo sapiens 84-110 7943259-3 1994 Eosinophils were isolated by negative immunoselection, and activation with 10(-7) M platelet-activating factor (PAF) was confirmed by measurements of eosinophil peroxidase (EPO) secretion and superoxide (O2-.) Superoxides 192-202 PCNA clamp associated factor Homo sapiens 112-115 7943259-3 1994 Eosinophils were isolated by negative immunoselection, and activation with 10(-7) M platelet-activating factor (PAF) was confirmed by measurements of eosinophil peroxidase (EPO) secretion and superoxide (O2-.) Superoxides 204-206 PCNA clamp associated factor Homo sapiens 84-110 7943259-3 1994 Eosinophils were isolated by negative immunoselection, and activation with 10(-7) M platelet-activating factor (PAF) was confirmed by measurements of eosinophil peroxidase (EPO) secretion and superoxide (O2-.) Superoxides 204-206 PCNA clamp associated factor Homo sapiens 112-115 7943259-6 1994 Similarly, PAF-induced O2-. Superoxides 23-25 PCNA clamp associated factor Homo sapiens 11-14 7981927-2 1994 It is known that in human polymorphonuclear leukocytes (PMNs), the phorbol ester-induced generation of superoxide anion (respiratory burst) is effectively inhibited by STAR in a dose-dependent manner, whereas superoxide generation induced by chemoattractants, e.g. n-formyl-methionyl-leucyl-phenylalanine (FMLP) or PAF, is regulated biphasically by STAR. Superoxides 103-113 PCNA clamp associated factor Homo sapiens 315-318 1321621-0 1992 Differential effects of platelet-activating factor on superoxide anion production in human eosinophils and neutrophils. Superoxides 54-70 PCNA clamp associated factor Homo sapiens 24-50 8342134-4 1993 We therefore undertook this study with the hypothesis that PAF-induced PMN superoxide production requires CD11B-mediated PMN-endothelial cell adherence. Superoxides 75-85 PCNA clamp associated factor Homo sapiens 59-62 8342134-7 1993 RESULTS: PAF induced prompt changes in PMN priming (increased superoxide production after N-formyl-methyl-leucyl-phenylalanine activation), adhesion to unstimulated endothelial cells, and CD11B receptor expression. Superoxides 62-72 PCNA clamp associated factor Homo sapiens 9-12 8389539-1 1993 In this study, it was presented that PAF and LTB4 exert a priming effect on PMNs to promote their superoxide anion production. Superoxides 98-114 PCNA clamp associated factor Homo sapiens 37-40 1487954-4 1992 In recent years, it also has been shown that serum platelet-activating factor (PAF) levels increased during ischemia-reperfusion, and that induction of superoxide generation by neutrophils is one of the important biological effects of PAF. Superoxides 152-162 PCNA clamp associated factor Homo sapiens 79-82 1487954-4 1992 In recent years, it also has been shown that serum platelet-activating factor (PAF) levels increased during ischemia-reperfusion, and that induction of superoxide generation by neutrophils is one of the important biological effects of PAF. Superoxides 152-162 PCNA clamp associated factor Homo sapiens 235-238 8383168-8 1993 PAF also stimulated superoxide anion production alone and in combination with the macrophage activator 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in both cell types. Superoxides 20-36 PCNA clamp associated factor Homo sapiens 0-3 1321621-1 1992 The effect of platelet-activating factor (PAF) on the generation of superoxide anion (O2-) in human eosinophils and neutrophils was examined. Superoxides 68-84 PCNA clamp associated factor Homo sapiens 14-40 1321621-1 1992 The effect of platelet-activating factor (PAF) on the generation of superoxide anion (O2-) in human eosinophils and neutrophils was examined. Superoxides 68-84 PCNA clamp associated factor Homo sapiens 42-45 1321621-1 1992 The effect of platelet-activating factor (PAF) on the generation of superoxide anion (O2-) in human eosinophils and neutrophils was examined. Superoxides 86-89 PCNA clamp associated factor Homo sapiens 14-40 1321621-1 1992 The effect of platelet-activating factor (PAF) on the generation of superoxide anion (O2-) in human eosinophils and neutrophils was examined. Superoxides 86-89 PCNA clamp associated factor Homo sapiens 42-45 1321621-2 1992 The presence of PAF potentiated O2- production in either opsonized zymosan- or formyl-methionyl-leucyl-phenylalanine (FMLP)-stimulated cells. Superoxides 32-34 PCNA clamp associated factor Homo sapiens 16-19 1321621-4 1992 We also found that eosinophils generate substantial amounts of O2- when treated with PAF alone. Superoxides 63-65 PCNA clamp associated factor Homo sapiens 85-88 1321621-5 1992 The high responsiveness of unstimulated or opsonized zymosan-stimulated eosinophils to PAF to generate O2- may be relevant to the pathological changes at the loci of allergic reactions where eosinophils and PAF are crucially involved. Superoxides 103-105 PCNA clamp associated factor Homo sapiens 87-90 1321621-5 1992 The high responsiveness of unstimulated or opsonized zymosan-stimulated eosinophils to PAF to generate O2- may be relevant to the pathological changes at the loci of allergic reactions where eosinophils and PAF are crucially involved. Superoxides 103-105 PCNA clamp associated factor Homo sapiens 207-210 1309421-0 1992 Platelet-activating factor primes human eosinophil generation of superoxide. Superoxides 65-75 PCNA clamp associated factor Homo sapiens 0-26 1314191-0 1992 Superoxide anion release induced by platelet-activating factor is increased in human alveolar macrophages from smokers. Superoxides 0-16 PCNA clamp associated factor Homo sapiens 36-62 1314191-1 1992 This study was designed to investigate the effects of the platelet-activating factor (PAF) on the superoxide anion production (O2.) Superoxides 98-114 PCNA clamp associated factor Homo sapiens 58-84 1314191-1 1992 This study was designed to investigate the effects of the platelet-activating factor (PAF) on the superoxide anion production (O2.) Superoxides 98-114 PCNA clamp associated factor Homo sapiens 86-89 1314191-1 1992 This study was designed to investigate the effects of the platelet-activating factor (PAF) on the superoxide anion production (O2.) Superoxides 127-129 PCNA clamp associated factor Homo sapiens 58-84 1314191-1 1992 This study was designed to investigate the effects of the platelet-activating factor (PAF) on the superoxide anion production (O2.) Superoxides 127-129 PCNA clamp associated factor Homo sapiens 86-89 1314191-4 1992 Stimulation with PAF led to a dose-dependent increase of O2. Superoxides 57-59 PCNA clamp associated factor Homo sapiens 17-20 1314191-6 1992 The median effective dose (EC50) for PAF action on O2. Superoxides 51-53 PCNA clamp associated factor Homo sapiens 37-40 1309421-5 1992 To test this hypothesis, eosinophils were preincubated (1 and 15 min) with low concentrations of PAF (1 x 10(-8) and 1 x 10(-10) M); this exposure to PAF resulted in enhanced generation of superoxide anion to FMLP stimulation. Superoxides 189-205 PCNA clamp associated factor Homo sapiens 97-100 1309421-5 1992 To test this hypothesis, eosinophils were preincubated (1 and 15 min) with low concentrations of PAF (1 x 10(-8) and 1 x 10(-10) M); this exposure to PAF resulted in enhanced generation of superoxide anion to FMLP stimulation. Superoxides 189-205 PCNA clamp associated factor Homo sapiens 150-153 1327185-3 1992 Stimulation of superoxide radical production strongly depends on the structure of the polar heads of PAF analogs. Superoxides 15-33 PCNA clamp associated factor Homo sapiens 101-104 1848228-6 1991 In functional studies GM-CSF stimulated superoxide anion generation from neutrophils with a time and dose relationship that paralleled PAF synthesis. Superoxides 40-56 PCNA clamp associated factor Homo sapiens 135-138 1668107-0 1991 Effect of platelet-activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Superoxides 70-80 PCNA clamp associated factor Homo sapiens 10-36 1668107-3 1991 PAF alone (0.1 pM to 0.1 nM) failed to evoke superoxide production; however, when PAF was added for 10 min to cells upon prior incubation with 10 ng/mL TNF for 50 min, superoxide production was significantly enhanced as compared to that induced by TNF alone. Superoxides 168-178 PCNA clamp associated factor Homo sapiens 82-85 1659593-0 1991 The effect of platelet-activating factor on the generation of superoxide anion in human eosinophils and neutrophils. Superoxides 62-78 PCNA clamp associated factor Homo sapiens 14-40 1659593-5 1991 Both granulocyte cell types generated O2- when they were incubated with PAF. Superoxides 38-40 PCNA clamp associated factor Homo sapiens 72-75 1667989-8 1991 Like CL, PAF had a weak effect on the generation of superoxide from PMNs. Superoxides 52-62 PCNA clamp associated factor Homo sapiens 9-12 1667989-9 1991 Neutrophils from seven RA SF stimulated with PMA or PAF showed a significant increase in superoxide production (76.05 +/- 2.14, 2.83 +/- 0.18) and these were higher than in PB of either RA patients (54.35 +/- 12.46, 1.03 +/- 0.74) and HS (55.70 +/- 17.9; 1.08 +/- 1.12) (p less than 0.05). Superoxides 89-99 PCNA clamp associated factor Homo sapiens 52-55 1646607-8 1991 The effects of PAF on [Ca2+]i and (O2-) could be blocked by the PAF-specific antagonist WEB 2086 dose dependently, indicating a receptor-mediated event. Superoxides 35-37 PCNA clamp associated factor Homo sapiens 64-67 1327185-1 1992 The effects of plasmalogenic and acyl structural analogs of the platelet activation factor (PAF) on the superoxide radical production by human blood leukocytes were studied. Superoxides 104-122 PCNA clamp associated factor Homo sapiens 92-95 1668107-6 1991 Pretreatment of the PMN with either pertussis or cholera toxin attenuated the PAF amplified superoxide production in TNF stimulated cells, suggesting that G proteins sensitive to these toxins may be involved in the mechanisms controlling amplification. Superoxides 92-102 PCNA clamp associated factor Homo sapiens 78-81 1668119-0 1991 Role of platelet-activating factor (PAF) in superoxide production by human polymorphonuclear leukocytes. Superoxides 44-54 PCNA clamp associated factor Homo sapiens 8-34 1668119-0 1991 Role of platelet-activating factor (PAF) in superoxide production by human polymorphonuclear leukocytes. Superoxides 44-54 PCNA clamp associated factor Homo sapiens 36-39 1668119-1 1991 The effect of platelet-activating factor (PAF) in superoxide production by human polymorphonuclear leukocytes (PMN) was studied. Superoxides 50-60 PCNA clamp associated factor Homo sapiens 14-40 1668119-1 1991 The effect of platelet-activating factor (PAF) in superoxide production by human polymorphonuclear leukocytes (PMN) was studied. Superoxides 50-60 PCNA clamp associated factor Homo sapiens 42-45 1668119-3 1991 PAF induced superoxide generation in human PMN in a dose-dependent manner. Superoxides 12-22 PCNA clamp associated factor Homo sapiens 0-3 1668119-4 1991 Preincubation with a small amount of PAF (5 x 10(-9) M) enhanced PMN superoxide release induced by various stimuli, such as phorbol myristate acetate (PMA), opsonized zymosan (OZ), calcium ionophore (A23187) and N-formyl-methionyl-leucyl-phenylalanine (FMLP). Superoxides 69-79 PCNA clamp associated factor Homo sapiens 37-40 1668119-5 1991 The PAF antagonist, CV-6209, inhibited superoxide production induced by PAF, but not that induced by other stimuli. Superoxides 39-49 PCNA clamp associated factor Homo sapiens 4-7 1668119-5 1991 The PAF antagonist, CV-6209, inhibited superoxide production induced by PAF, but not that induced by other stimuli. Superoxides 39-49 PCNA clamp associated factor Homo sapiens 72-75 1646607-7 1991 PAF increased the production of superoxide anion (O2-) by human alveolar macrophages in a dose- dependent manner. Superoxides 32-48 PCNA clamp associated factor Homo sapiens 0-3 1646607-7 1991 PAF increased the production of superoxide anion (O2-) by human alveolar macrophages in a dose- dependent manner. Superoxides 50-52 PCNA clamp associated factor Homo sapiens 0-3 1646607-8 1991 The effects of PAF on [Ca2+]i and (O2-) could be blocked by the PAF-specific antagonist WEB 2086 dose dependently, indicating a receptor-mediated event. Superoxides 35-37 PCNA clamp associated factor Homo sapiens 15-18 1665713-4 1991 There was a close relationship between the concentration-response curve for increases in PAF synthesis and that for enhanced O2- generation. Superoxides 125-127 PCNA clamp associated factor Homo sapiens 89-92 1665713-5 1991 The possibility that PAF was causally linked to enhanced O2- generation in primed PMNs was investigated using compounds previously reported to reduce PAF generation, namely the serine protease inhibitor, tosyl-phenylalanine chloromethylketone, and the phospholipase A2 inhibitor, bromophenacylbromide. Superoxides 57-59 PCNA clamp associated factor Homo sapiens 21-24 1665713-7 1991 We examined the possibility that PAF acted in an autocrine fashion to enhance O2- generation following its release from fMLP-stimulated PMNs. Superoxides 78-80 PCNA clamp associated factor Homo sapiens 33-36 1647806-2 1991 All compounds were potent inhibitors of formyl-methionyl-leucyl-phenylalanine (FMLP)- and platelet-activating factor (PAF)-induced superoxide anion generation, beta-glucuronidase release and Ca++ influx. Superoxides 131-147 PCNA clamp associated factor Homo sapiens 118-121 1849872-2 1991 Both PAF and LTB4 are candidate mediators for the enhanced O2- generation in cytokine-primed PMN, since exogenous PAF or LTB4 primes PMN. Superoxides 59-61 PCNA clamp associated factor Homo sapiens 5-8 1849872-2 1991 Both PAF and LTB4 are candidate mediators for the enhanced O2- generation in cytokine-primed PMN, since exogenous PAF or LTB4 primes PMN. Superoxides 59-61 PCNA clamp associated factor Homo sapiens 114-117 1964761-1 1990 Nedocromil sodium (10(-10) - 10(-9) M) produced a dose-related inhibition of superoxide anion generation induced by platelet activating factor (PAF) in human polymorphonuclear leukocytes (PMNs). Superoxides 77-93 PCNA clamp associated factor Homo sapiens 116-142 1964761-1 1990 Nedocromil sodium (10(-10) - 10(-9) M) produced a dose-related inhibition of superoxide anion generation induced by platelet activating factor (PAF) in human polymorphonuclear leukocytes (PMNs). Superoxides 77-93 PCNA clamp associated factor Homo sapiens 144-147 1964761-0 1990 Differential inhibition by nedocromil sodium of superoxide generation elicited by platelet activating factor in human neutrophils. Superoxides 48-58 PCNA clamp associated factor Homo sapiens 82-108 1964761-4 1990 The preferential inhibitory effects of nedocromil sodium on PAF-induced activation of superoxide generation may provide insight into the therapeutic action of this drug as an anti-asthmatic agent. Superoxides 86-96 PCNA clamp associated factor Homo sapiens 60-63 1966814-3 1990 Although a relatively weak direct oxidative agonist, PAF markedly enhances O2- release evoked by phorbol myristate acetate (PMA) and the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP), increasing the maximal rate of O2- production by a calcium-dependent mechanism. Superoxides 75-77 PCNA clamp associated factor Homo sapiens 53-56 2240225-1 1990 The objective of this study was to assess whether superoxide and leukocyte adhesion glycoproteins (CD18) mediate the leukocyte adherence to mesenteric microvessels and increased intestinal microvascular permeability induced by platelet-activating factor (PAF). Superoxides 50-60 PCNA clamp associated factor Homo sapiens 227-253 2240225-1 1990 The objective of this study was to assess whether superoxide and leukocyte adhesion glycoproteins (CD18) mediate the leukocyte adherence to mesenteric microvessels and increased intestinal microvascular permeability induced by platelet-activating factor (PAF). Superoxides 50-60 PCNA clamp associated factor Homo sapiens 255-258 2240225-6 1990 Adherence of PAF-activated cat neutrophils to plastic was reduced only by MoAb IB4, suggesting that PAF-induced leukocyte adherence is mediated by both CD18 and superoxide and that endothelium is necessary for the superoxide-mediated adhesion. Superoxides 161-171 PCNA clamp associated factor Homo sapiens 13-16 2240225-6 1990 Adherence of PAF-activated cat neutrophils to plastic was reduced only by MoAb IB4, suggesting that PAF-induced leukocyte adherence is mediated by both CD18 and superoxide and that endothelium is necessary for the superoxide-mediated adhesion. Superoxides 161-171 PCNA clamp associated factor Homo sapiens 100-103 2240225-6 1990 Adherence of PAF-activated cat neutrophils to plastic was reduced only by MoAb IB4, suggesting that PAF-induced leukocyte adherence is mediated by both CD18 and superoxide and that endothelium is necessary for the superoxide-mediated adhesion. Superoxides 214-224 PCNA clamp associated factor Homo sapiens 13-16 2240225-6 1990 Adherence of PAF-activated cat neutrophils to plastic was reduced only by MoAb IB4, suggesting that PAF-induced leukocyte adherence is mediated by both CD18 and superoxide and that endothelium is necessary for the superoxide-mediated adhesion. Superoxides 214-224 PCNA clamp associated factor Homo sapiens 100-103 2240225-8 1990 These data indicate that the increased microvascular permeability induced by PAF can be attenuated when leukocyte adherence to microvascular endothelium is reduced using molecules that either bind to CD18 adhesive glycoproteins or scavenge superoxide. Superoxides 240-250 PCNA clamp associated factor Homo sapiens 77-80 2158320-2 1990 Low STAR concentrations from 10 to 200 nM potentiated the N-formyl-methionyl-leucyl-phenylalanine (fMLP) and platelet activating factor (Paf)-induced respiratory burst, affecting both the initial rate and the total amount of superoxide anion generated. Superoxides 225-241 PCNA clamp associated factor Homo sapiens 137-140 1966810-0 1990 Tumor necrosis factor alpha "primes" the platelet-activating factor-induced superoxide production by human neutrophils: possible involvement of G proteins. Superoxides 76-86 PCNA clamp associated factor Homo sapiens 41-67 1966810-2 1990 We were interested to ascertain whether superoxide generation by human PMN could be amplified by PAF following initial stimulation with tumor necrosis factor (TNF) and the effect of cholera and pertussis toxin on this process. Superoxides 40-50 PCNA clamp associated factor Homo sapiens 97-100 1966814-3 1990 Although a relatively weak direct oxidative agonist, PAF markedly enhances O2- release evoked by phorbol myristate acetate (PMA) and the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP), increasing the maximal rate of O2- production by a calcium-dependent mechanism. Superoxides 236-238 PCNA clamp associated factor Homo sapiens 53-56 1966810-3 1990 PAF alone (0.1 pM-0.1 nM) failed to evoke any superoxide production; however, when PAF was added for 10 min to cells previously incubated for 50 min with 10 ng/ml TNF, superoxide production was significantly enhanced relative to that induced by TNF alone. Superoxides 168-178 PCNA clamp associated factor Homo sapiens 83-86 1966810-5 1990 The PAF antagonists also decreased by 25% the superoxide production elicited solely by TNF, indicating that TNF-induced superoxide generation is partially mediated by a mechanism involving endogenous PAF. Superoxides 46-56 PCNA clamp associated factor Homo sapiens 4-7 1966810-5 1990 The PAF antagonists also decreased by 25% the superoxide production elicited solely by TNF, indicating that TNF-induced superoxide generation is partially mediated by a mechanism involving endogenous PAF. Superoxides 120-130 PCNA clamp associated factor Homo sapiens 4-7 1966810-5 1990 The PAF antagonists also decreased by 25% the superoxide production elicited solely by TNF, indicating that TNF-induced superoxide generation is partially mediated by a mechanism involving endogenous PAF. Superoxides 120-130 PCNA clamp associated factor Homo sapiens 200-203 1966810-6 1990 Pretreatment of the PMN with pertussis or cholera toxin reduced the amplification of superoxide production induced by PAF in TNF-stimulated PMN, implicating pertussis and cholera toxin-sensitive G-proteins in the amplification process. Superoxides 85-95 PCNA clamp associated factor Homo sapiens 118-121 2562430-5 1989 In contrast PAF appears to be only a weak stimulus of superoxide anion production (compared to the phorbol ester phorbol 12-myristate 13-acetate (PMA] and leukotriene B4 (LTB4) synthesis (compared to the Ca2+ ionophore A23187). Superoxides 54-70 PCNA clamp associated factor Homo sapiens 12-15 2541198-8 1989 PAF also caused generation of superoxide anions by human eosinophils but this occurred at higher concentrations of PAF (1 microM to 30 microM) with an ED50 of 8.4 +/- 0.9 microM. Superoxides 30-47 PCNA clamp associated factor Homo sapiens 0-3 2541198-10 1989 These studies demonstrate that PAF activates human eosinophils to release granule constituents and generate superoxide anions. Superoxides 108-125 PCNA clamp associated factor Homo sapiens 31-34 2451547-3 1988 PAF priming of responses including superoxide generation, elastase release, and aggregation is time dependent and is maximal within five minutes. Superoxides 35-45 PCNA clamp associated factor Homo sapiens 0-3 2846728-0 1988 Influence of platelet activating factor and a nonmetabolizable analogue on superoxide production by bone marrow derived macrophages. Superoxides 75-85 PCNA clamp associated factor Homo sapiens 13-39 3192624-1 1988 We have shown that platelet-activating factor (PAF), a weak primary stimulus for neutrophil superoxide generation, synergistically enhances neutrophil oxidative responses to the tumor promoter phorbol myristate acetate (PMA). Superoxides 92-102 PCNA clamp associated factor Homo sapiens 19-45 3192624-1 1988 We have shown that platelet-activating factor (PAF), a weak primary stimulus for neutrophil superoxide generation, synergistically enhances neutrophil oxidative responses to the tumor promoter phorbol myristate acetate (PMA). Superoxides 92-102 PCNA clamp associated factor Homo sapiens 47-50 2836040-1 1988 Previous studies in burned patients have shown an early enhanced polymorphonuclear leucocyte (PMN) generating capacity for superoxide radical (O2.-), for the arachidonic acid (AA) lipoxygenase metabolite leukotriene B4 (LTB4) and for platelet activating factor-acether (PAF). Superoxides 123-141 PCNA clamp associated factor Homo sapiens 234-274 2836040-1 1988 Previous studies in burned patients have shown an early enhanced polymorphonuclear leucocyte (PMN) generating capacity for superoxide radical (O2.-), for the arachidonic acid (AA) lipoxygenase metabolite leukotriene B4 (LTB4) and for platelet activating factor-acether (PAF). Superoxides 143-145 PCNA clamp associated factor Homo sapiens 234-274 3006836-1 1986 The role of platelet activating factor (PAF) as a regulator of human neutrophil superoxide (O2-) generation in response to soluble and particulate stimuli was examined. Superoxides 80-90 PCNA clamp associated factor Homo sapiens 40-43 3006836-1 1986 The role of platelet activating factor (PAF) as a regulator of human neutrophil superoxide (O2-) generation in response to soluble and particulate stimuli was examined. Superoxides 92-95 PCNA clamp associated factor Homo sapiens 40-43 3006836-2 1986 At concentrations greater than 10(-7) mol/L, PAF alone induced a brief burst of O2- production. Superoxides 80-82 PCNA clamp associated factor Homo sapiens 45-48 2825844-9 1988 These results suggest that PAF induces an increase in particulate protein kinase activity in neutrophils by a calcium-dependent mechanism and that the induction of membrane-associated protein kinase activity may be involved in neutrophil-stimulating actions such as superoxide production, which occur at higher concentrations of PAF. Superoxides 266-276 PCNA clamp associated factor Homo sapiens 27-30 2825844-9 1988 These results suggest that PAF induces an increase in particulate protein kinase activity in neutrophils by a calcium-dependent mechanism and that the induction of membrane-associated protein kinase activity may be involved in neutrophil-stimulating actions such as superoxide production, which occur at higher concentrations of PAF. Superoxides 266-276 PCNA clamp associated factor Homo sapiens 329-332 3038160-4 1987 PAF enhanced FMLP-elicited superoxide release in a dose-dependent fashion. Superoxides 27-37 PCNA clamp associated factor Homo sapiens 0-3